文献速递哮喘呼吸道感染

过敏原免疫治疗可降低季节性和常年性过敏性哮喘的急性发作与下呼吸道感染风险:一项全国性流行病学研究

Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study.
PubMed 文献 · Eur Respir J · 2022-11-17

该研究基于全国性前瞻性登记数据,纳入1995-2014年间接受过敏原免疫治疗(AIT)的18-44岁哮喘患者2688例,分为常年性过敏性哮喘(PAA,1249例)和季节性过敏性哮喘(SAA,1439例)。结果显示,AIT治疗后3年随访期间,PAA和SAA的急性发作平均分别减少57%和74%,下呼吸道感染(LRTI)分别减少17%和20%。结论认为AIT可有效降低两类过敏性哮喘的急性发作和LRTI风险,且常年性过敏似乎并不比季节性过敏是更强的危险因素。

要点

  • AIT可显著降低季节性和常年性过敏性哮喘的急性发作风险。
  • AIT可显著降低两类过敏性哮喘的下呼吸道感染风险。
  • 常年性过敏并非比季节性过敏更强的呼吸道感染或急性发作危险因素。

核心结论

  • AIT有效降低了季节性和常年性过敏性哮喘的急性发作和下呼吸道感染风险。
  • 常年性过敏似乎并不比季节性过敏是更强的呼吸道感染和急性发作危险因素。

研究设计与样本

  • 这是一项基于前瞻性登记数据的全国性研究,纳入1995-2014年间接受AIT治疗的18-44岁患者。
  • 共识别2688例接受AIT治疗的哮喘患者,其中常年性过敏性哮喘(PAA)1249例,季节性过敏性哮喘(SAA)1439例。
  • 根据AIT类型和抗哮喘药物使用情况将患者分为PAA和SAA两组,分析AIT开始前(基线)和完成AIT后3年(随访)的数据。

主要发现

  • 基线时,SAA患者急性发作比例高于PAA患者(23.8% vs 16.5%,p≤0.001),但下呼吸道感染(LRTI)无差异。
  • 3年随访期间,PAA患者急性发作平均减少57%,SAA患者平均减少74%。
  • PAA和SAA患者LRTI分别显著减少17%和20%。

临床怎么用

  • 对于季节性和常年性过敏性哮喘患者,可考虑使用AIT以降低急性发作和下呼吸道感染风险。
  • 临床中不应仅因过敏原为常年性而认为其呼吸道感染或急性发作风险高于季节性过敏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergic asthma is associated with increased risk of respiratory tract infections and exacerbations. It remains unclear whether this susceptibility is conditioned by seasonal or by perennial allergy. AIM: To investigate perennial allergy compared with seasonal allergy as a risk factor for lower respiratory tract infections and exacerbations in asthma and whether this risk can be reduced by allergen immunotherapy (AIT). METHODOLOGY: This is a prospective register-based nationwide study of 18-44-year-olds treated with AIT during 1995-2014. Based on the type of AIT and use of anti-asthmatic drugs, patients were subdivided into two groups: perennial allergic asthma (PAA) versus seasonal allergic asthma (SAA). Data on antibiotics against lower respiratory tract infections (LRTI) and oral corticosteroids for exacerbations were analysed before starting AIT (baseline) and 3 years after completing AIT (follow-up). RESULTS: We identified 2688 patients with asthma treated with AIT, of whom 1249 had PAA and 1439 had SAA. At baseline, patients with SAA had more exacerbations (23.8% versus 16.5%, p≤0.001), but there were no differences in LRTI. During the 3-year follow-up, we observed a highly significant reduction of exacerbations with an average decrease of 57% in PAA and 74% in SAA. In addition, we observed a significant reduction of LRTI in both PAA and SAA: 17% and 20% decrease, respectively. CONCLUSION: AIT effectively reduced the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma. Perennial allergy is seemingly not a stronger risk factor for respiratory infections and exacerbations than seasonal allergy.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Woehlk C, Von Bülow A, Ghanizada M, et al. Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study. Eur Respir J. 2022. PMID: 35618279. doi:10.1183/13993003.00446-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。